US 12,240,872 B2
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
David B. Weiner, Merion, PA (US); Ami Patel, Philadelphia, PA (US); and Jian Yan, Wallingford, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); The Wistar Institute of Anatomy and Biology, Plymouth Meeting, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on Aug. 17, 2021, as Appl. No. 17/404,143.
Application 17/404,143 is a continuation of application No. 16/098,912, granted, now 11,091,518, previously published as PCT/US2017/031215, filed on May 5, 2017.
Claims priority of provisional application 62/483,979, filed on Apr. 11, 2017.
Claims priority of provisional application 62/402,519, filed on Sep. 30, 2016.
Claims priority of provisional application 62/332,372, filed on May 5, 2016.
Prior Publication US 2021/0388033 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 9/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 31/12 (2006.01); C07K 14/54 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 9/0009 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61P 31/12 (2018.01); C07K 14/54 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55538 (2013.01); A61K 2039/58 (2013.01); A61K 2039/70 (2013.01); C07K 2319/02 (2013.01); C12N 2760/14122 (2013.01); C12N 2760/14134 (2013.01)] 17 Claims
 
1. An isolated nucleic acid molecule comprising a nucleic acid encoding a consensus Zaire ebolavirus envelope glycoprotein immunogen (ZEBOVCON2), wherein the ZEBOVCON2 comprises an amino acid sequence as set forth in SEQ ID NO:68, or a fragment of an amino acid sequence comprising at least 600 consecutive amino acid residues of SEQ ID NO:68.